# A First-in-Human Single and Multiple Ascending Dose Study of MT-251

> **NCT07423299** · PHASE1 · RECRUITING · sponsor: **Mirador Therapeutics, Inc.** · enrollment: 70 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** MT-251

## Key facts

- **NCT ID:** NCT07423299
- **Lead sponsor:** Mirador Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-23
- **Primary completion:** 2027-03-08
- **Final completion:** 2027-03-08
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07423299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07423299, "A First-in-Human Single and Multiple Ascending Dose Study of MT-251". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07423299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*